The AIO - Working Group on Internal Oncology in the German Cancer Society is a scientific organization within the German Cancer Society. Founded in 1976, it conducts clinical studies and supports quality assurance in drug-based tumor therapies through interdisciplinary collaboration.
The group has more than 1,500 members active in over 20 working groups and operates related non-profit entities focused on oncology research.
Also known as Arbeitsgemeinschaft Internistische Onkologie (AIO) and Internal Oncology Working Group (AIO).
None yet. When a new project in the record names AIO as owner, partner or investor, it shows here.
FDA backs first adjuvant immunotherapy regimen for stage III dMMR colon cancer after ATOMIC showed a 50% reduction in recurrence or death with Tecentriq added to chemotherapy.
FDA accepted an sBLA for adjuvant PD‑L1 therapy plus chemotherapy in stage III dMMR/MSI‑H colon cancer; agency decision expected Oct 9, 2026.
